Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi US (EURONEXT: SAN and NYSE: SNY) are working together with various patient and Professional Heart Disease Organizations to initiate Cholesterol Counts. It is an awareness program that will survey how much Americans know about the figures related to Cholesterol and the various dangers linked to high LDL-C or bad cholesterol.
All American Adults are encouraged to go to www.CholesterolCounts.com and take a short poll. It will provide various answers along with few questions related to their health. The results concluded from this poll will provide an insight into the cholesterol awareness levels across the country. It will be published in 2015.
In the United States, diseases and disorders related to the heart are the number one cause of most fatalities. Michele Packard-Milam, CAE, Executive Director of Mended Hearts, states that their organization works with various patients who have experienced a grave health consequences as a result of high bad cholesterol, like strokes and heart attacks.
It is highly imperative that people talk to their doctors in order to make themselves aware of the dangers posed due to high bad cholesterol levels. He declared that with The Cholesterol Counts Program, will measure as to how many people are aware regarding their cholesterol levels. Sanofi US and Regeneron are engaging with Foundation of the National Lipid Association (FNLA), Mended Hearts and Preventive Cardiovascular Nurses Association (PCNA) for The Cholesterol Counts Program.
Build-up of cholesterol plaque in arteries leading to heart attacks and strokes is an increasing concern in America. Knowing how much the people are aware regarding these issues will certainly help in the near future. In spite of advanced technologies and treatment options that promote healthy diets, and a good lifestyle, the figures regarding the impact of high cholesterol remain staggering.
An estimated 71 million people suffering from the effects of High Bad Cholesterol levels, less than half are being subjected to a valid lipid-lowering therapy. Figuring out the gaps between the treatment and identification of High Cholesterol will be facilitated by The Cholesterol Counts Program. It will give rise to a better awareness and treatment options in U.S.A.
The experimental anti-cholesterol PCSK9 alirocumab by Sanofi and Regeneron is expected to get into the race with the investigational evolocumab from Amgem. It is already laying down the law regarding the groundwork for helping Americans get aware regarding High LDL-C.
The survey will ask many different questions that are associated with the risks involving high LDL-C. These include questions regarding how smoking, diet or exercise can affect the cholesterol levels in a common individual. The poll also questions people regarding their use of prescription cholesterol-fighters and whether they have talked to doctors regarding Heart Health.